- 7 of 16 (44%) patients achieved best overall response of partial response
- Confirmed response in 5 of 7 (71%) patients who had at least 16 weeks of follow-up
- 14 of 16 (88%) patients demonstrated tumor decrease from baseline
- Batiraxcept has been well-tolerated with no dose-limiting toxicities
San Francisco, CA (UroToday.com) — Aravive, Inc., a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, announced positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC). A subset of these data was included in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021.